Cisplatin Pharmacokinetics in Nontumoral Pig Liver Treated With Intravenous or Transarterial Hepatic Chemoembolization

详细信息    查看全文

• 作者：Pascal Chabrot (1) (2)
  Jean-Michel Cardot (3)
  Pierre Guibert (4)
  Fran?ois Bouculat (4)
  Lucie Cassagnes (1) (2)
  Anne Léger-Enreille (5)
  Emmanuel Buc (4)
  Pierre Dechelotte (6)
  Gilles Bommelaer (4)
  Louis Boyer (1) (2)
  Armand Abergel (2) (4)
  
• 关键词：Interventional oncology ; Animal experiments ; Chemoembolization ; Cisplatin ; Pharmacokinetics ; Intra ; arterial chemotherapy
• 刊名：CardioVascular and Interventional Radiology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：35
• 期：6
• 页码：1467-1474
• 全文大小：318KB
• 参考文献：1. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-236 CrossRef
  2. Llovet JM et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-739 CrossRef
  3. Lo CM et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-171 CrossRef
  4. Daniels JR, Wallman M (2010) Subselective intra-arterial chemotherapy infusion in the treatment of hepatocellular carcinoma. Semin Oncol 37(2):83-8 CrossRef
  5. Egawa H et al (1990) Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 44(2):109-14 CrossRef
  6. Konno T (1990) Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 66(9):1897-903 CrossRef
  7. Nakamura H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170(3 Pt 1):783-86
  8. Sasaki Y et al (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60(6):1194-203 CrossRef
  9. Marelli L et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30(1):6-5 CrossRef
  10. Chen PJ et al (2010) Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts-opinion. Liver Int 30(10):1427-438
  11. Stewart DJ et al (1983) Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum(II). Cancer Res 43(2):917-20
  12. Johnson PJ et al (1991) Pharmacokinetics and toxicity of intra-arterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13(1):120-27 CrossRef
  13. Dzodic R et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 15(6):647-50 CrossRef
  14. Cagol PP, Pasqual E, Bacchetti S (2006) Potential advantages of loco-regional intra-arterial chemotherapy. In Vivo 20(6A):777-79
  15. Kelsen DP et al (1982) Pharmacokinetics of cisplatin regional hepatic infusions. Am J Clin Oncol 5(2):173-78 CrossRef
  16. Ding JW et al (1992) Pharmacokinetics of mitomycin C following hepatic arterial chemoembolization with gelfoam. HPB Surg 5(3):161-67 (discussion 167-69) CrossRef
  17. Civalleri D et al (1991) Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases. Cancer 68(5):988-94 CrossRef
  18. Sadahiro S et al (2003) Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. Jpn J Clin Oncol 33(8):377-81 CrossRef
  19. Barone R (ed) (1996) Anatomie comparée des mamifères domestiques, 5th edn. Angiologie, Vigot, Paris
  20. Zhang L et al (2004) Study of hepatic function matching between Banna minipig inbred and humans. Transplant Proc 36(8):2492-494 CrossRef
  21. Charte nationale portant sur l’expérimenation animale (2008) http://www.enseignementsup-recherche.gouv.fr/cid28541/la-charte-nationale-portant-sur-l-ethique-de-l-experimentation-animale.html
  22. Shin SW (2009) The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 10(5):425-34 CrossRef
  23. Pera MF Jr, Harder HC (1977) Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23(7):1245-124
  24. Bannister SJ et al (1978) Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II). Clin Chem 24(6):877-80
  25. Litterst CL et al (1976) Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36(7 Pt 1):2340-344
  26. Vexler AM et al (1995) Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. Int J Cancer 60(5):611-15 CrossRef
  27. Kruh GD (2003) Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 9(16 Pt 1):5807-809
  28. Raoul JL et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70(3):585-90 CrossRef
  
• 作者单位：Pascal Chabrot (1) (2)
  Jean-Michel Cardot (3)
  Pierre Guibert (4)
  Fran?ois Bouculat (4)
  Lucie Cassagnes (1) (2)
  Anne Léger-Enreille (5)
  Emmanuel Buc (4)
  Pierre Dechelotte (6)
  Gilles Bommelaer (4)
  Louis Boyer (1) (2)
  Armand Abergel (2) (4)
  
  1. P?le de Radiologie, CHU Clermont-Ferrand, 58 Rue Montalembert, 63000, Clermont-Ferrand, France
  2. ISIT, UMR CNRS 6284, Université d’Auvergne Clermont 1, Faculté de Médecine, Place Henri Dunant, 63000, Clermont-Ferrand, France
  3. Service de Biopharmacie, Université d’Auvergne Clermont 1, Faculté de Pharmacie, Place Henri Dunant, 63000, Clermont-Ferrand, France
  4. P?le Digestif et Hépato-Biliaire, CHU Clermont-Ferrand, 1 Place Lucie Aubrac, 63100, Clermont-Ferrand, France
  5. Service de Biologie, Centre Jean Perrin, 58 Rue Montalembert, 63000, Clermont-Ferrand, France
  6. Service d’Anatomie-Pathologique, CHU Clermont-Ferrand, 1 Place Lucie Aubrac, 63100, Clermont-Ferrand, France
  
• ISSN：1432-086X

文摘

Purpose To evaluate cisplatin (CDDP) pharmacokinetics after its intravenous (IV) or intrahepatic arterial administration (IHA) in healthy pigs with or without embolization by absorbable gelatine. Material and Methods We analysed plasmatic and hepatic drug concentration in four groups of six mini-pigs each according to the modality of administration of CDDP (1?mg/kg): IV, IHA, IHA with partial embolization using absorbable gelatine (IHA-Pe), and IHA with complete embolization (IHA-Te). Unbounded plasmatic and hepatic platinum concentrations were measured. Concentration and pharmacokinetics parameters were compared using analysis of variance. Results For all groups, there was a rapid and biexponential decrease in free platinum concentration. Plasmatic terminal half-life (T1/2) was significantly decreased after embolization at 191, 178, 42, and 41?min after IV, IHA, IHA-Pe, and IHA-Te administration, respectively. Maximal plasmatic concentration and systemic exposure to CDDP (AUC24) values were significantly decreased after embolization (Cmax p?=?0.0075; AUC24 p?=?0.0053). Hepatic CDDP concentration rapidly peaked and then decreased progressively. After 24?h, the residual concentration represented 45, 47, 60, and 63?% of Cmax, respectively, after IV, IHA, IHA-Pe, and IHA-Te. Hepatic T1/2 and AUC?/sub> values were increased after embolization, but the differences were not statistically significant. Conclusion This preliminary study confirms the feasibility of a pig model to study systemic and hepatic CDDP pharmacokinetics. Systemic exposure is lower after embolization, which could minimize systemic toxicity. Hepatic T1/2 elimination and hepatic exposition values are increased with IHA compared with IV administration.